Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a
CD30-positive T cell lymphoma characterized by signalling from constitutively activated ALK …

Approximately 30% of pediatric patients with anaplastic large cell lymphoma (ALCL)
relapse. Although brentuximab vedotin has demonstrated excellent activity in ALCL, it has …

Molecular monitoring of tumor-derived alterations has an established role in the surveillance
of leukemias, and emerging nucleic acid sequencing technologies are likely to similarly …

PURPOSE Arm crizotinib (CZ) of the Children's Oncology Group trial ANHL12P1
(ClinicalTrials. gov identifier: NCT01979536) examined the efficacy and toxicity of adding CZ …

Pediatric non‐Hodgkin lymphoma (NHL) includes over 30 histologies (many with subtypes),
with approximately 800 cases per year in the United States. Improvements in survival in NHL …

Simple Summary Detection of minimal disease in blood or bone marrow is associated with
high relapse risk in children with anaplastic large cell lymphoma (ALCL). The persistence of …

ALK-positive anaplastic large cell lymphoma (ALCL) represents approximately 6–7% of the
mature T-cell lymphomas. This subtype contains a translocation between the ALK gene on …

Simple Summary Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell
lymphoma (ALCL) is an aggressive T-cell lymphoma characterized by large T-cells with …

T-cell lymphoma is a highly invasive tumor with significant heterogeneity. Invasive tissue
biopsy is the gold standard for acquiring molecular data and categorizing lymphoma …

Peripheral T-cell lymphomas (PTCL) comprised more than 30 rare heterogeneous entities,
representing 10 to 15% of adult non-Hodgkin lymphomas. Although their diagnosis is still …